Аннотация:To the Editor: The clinical benefit of vancomycin, useful for over 30 years in the treatment of patients infected with gram-positive bacteria, has recently been compromised by the development of resistance — especially by enterococci.1 The Centers for Disease Control and Prevention (CDC) have drafted guidelines for the judicious use of vancomycin in an effort to minimize selection for these strains.2 We are concerned that Medicare reimbursement policies may result in increased use of vancomycin. As the largest national purchaser of health care, the Medicare program can profoundly influence health care delivery through its reimbursement policies. Medicare does not routinely . . .
